THE ROLE OF NANOTECHNOLOGY IN DRUG DEVELOPMENT FROM MEDICINAL PLANTS

Year 2026, Volume: 7 Issue: 2, 49 - 60, 09.03.2026

Rıdvan Lawal , Mehmet Özaslan , Dayo Adedoyin , Obumneme Okoye

https://doi.org/10.55549/zbs.928475

https://izlik.org/JA67KT47KU

Abstract

Nanotechnology involves the manipulation of matter at atomic, molecular, and supramolecular levels (Ramsden, 2009). One medicinal plant that has gained significance in nanotechnology applications is turmeric. The rhizome of Curcuma longa, traditionally used for decades as a spice, coloring agent, and food preservative, has been identified as a rich source of phenolic compounds (Sa and Das, 2008). However, the primary challenge in utilizing curcumin, its active component, is its low bioavailability (Ahmad et al., 2007). This limitation arises due to its poor stability and low aqueous solubility, necessitating the consumption of large doses to achieve therapeutic effects (Wang et al., 2008). Such high doses are impractical for clinical trials. Nanotechnology offers a solution by transforming turmeric extracts into water-soluble nanocrystals, approximately 250 nm in size. These curcumin nanoparticles have shown great potential in treating diseases such as cancer, microbial infections, and even HIV (Thorat and Dalvi, 2012). Among the numerous advantages of nanotechnology in drug development, it enables the fabrication of active phytochemicals with enhanced drug-targeting capabilities. This has led to the emergence of various technologies that leverage the unique properties of nanoscale structures (Aulton, 2007). Innovations such as nanocrystals, solid lipid nanoparticles (SLNs), nanoemulsions, and polymeric nanoparticles have helped overcome key challenges related to poor solubility, limited bioavailability, and chemical instability in drug development from medicinal plants (Pletonen and Hinnoven, 2010).

Keywords

plants , Nanotechnology , drugs , medicinal , therapy

Ethical Statement

N/A

Supporting Institution

N/A

Project Number

N/A

Thanks

N/A

References

• Ahmad M, Basheer S, Mughram MHA, Iqbal DN, Qamar S, Saeed A, et al. (2024) Structural development of curcumin: a natural product arsenal for diverse therapeutic targets—seizing opportunities through serendipity and rational design. J Mol Struct. 1324:140815.
• Aulton M. E. (2007) Pharmaceutics: The design and manufacture of medicines, 3rd edition, Churchill Livingstone, London UK, 2007
• Bhushan, B. (2011). Springer Handbook of Nanotechnology. Springer Science & Business Media. Binnig, G., & Rohrer, H. (1982) Scanning Tunneling Microscopy. Helvetica Physica Acta, 55(6): 726-735.
• Dhanokar, R. D., Jatale, A. P., Deshmukh, S. P., Mangesh k Hir (2023). Nanotechnology for Enhancing the Bioavailability of Herbal drug. International Journal of Creative Research Thoughts, 11(10): d790-d801.
• El-Sayed, M. A. (2016). Recent Nanotechnology Approaches for Prevention and Treatment of Biofilms on Biomedical Materials. Advanced Healthcare Materials, 5(22), 2868-2885.
• Fabricant, D. S., & Farnsworth, N. R. (2001). The value of plants used in traditional medicine for drug discovery. Environmental Health Perspectives, 109(1): 69-75.
• Feynman, R. (1960) There’s Plenty of Room at the Bottom. Engineering and Science, 23(5), 22-36.
• Gupta, S. C., Sung, B., Kim, J. H., Prasad, S., Li, S., & Aggarwal, B. B. (2008). Multitargeting by turmeric: The molecular targets underlying curcumin’s therapeutic effects. Trends in Pharmacological Sciences, 29(9), 518-527.
• Iijima, S. (1991) Helical microtubules of graphitic carbon. Nature, 354(6348): 56-58.
• Kroto, H. W., Heath, J. R., O’Brien, S. C., Curl, R. F., & Smalley, R. E. (1985) C60: Buckminsterfullerene. Nature, 318(6042): 162-163.
• Newman, D. J., & Cragg, G. M. (2016). Natural products as sources of new drugs from 1981 to 2014. Journal of Natural Products, 79(3), 629-661.
• Peltonen, L, Hirvonen, J (2010) Pharmaceutical nanocrystals by nanomilling: critical process parameters, particle fracturing and stabilisation methods. Journal of Pharmacy and Pharmacology, 62, 1569-1579
• Ramsden J. (2009). What is nanotechnology?. Applied nanotechnology. 3-12.
• Rates, S. M. K. (2001). Plants as source of drugs. Toxicon, 39(5), 603-613.
• Roco, M. C. (2003) Nanotechnology: convergence with modern biology and medicine. Current Opinion in Biotechnology, 14(3): 337-346.
• Sa G, Das T (2008) Anti-cancer effects of curcumin: cycle of life and death. Cell Div 3: 14
• Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2020). Cancer nanomedicine: progress, challenges and opportunities. Nature Reviews Cancer 20(4), 203-217.
• Taniguchi, N. (1974) On the Basic Concept of ‘Nano-Technology’. Proceedings of the International Conference on Production Engineering, Tokyo, 5.
• Thorat, A. A., Dalvi, S. V. (2012). Solid-state and dissolution characteristics of nanocrystalline curcumin. AAPS Pharm Sci Tech, 13(3), 1031-1040.
• Wang L.Y., Mian Zhang, Chao-Feng Zhang, Zheng-Tao Wang (2008) Diaryl derivatives from the root tuber of Curcuma longa. Biochem. Syst. Ecol. 36, (5–6): 476-480
• World Health Organization (2013). WHO Traditional medicine strategy 2014-2023. Geneva: World Health Organization. (2013). Available at: https://iris.who.int/bitstream/handle/10665/92455/9789241506090_eng.pdf?sequence=1